Brokerages Set Trillium Therapeutics Inc. (TRIL) Target Price at $24.25
Shares of Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) have earned a consensus recommendation of “Buy” from the seven analysts that are covering the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $24.25.
Separately, Zacks Investment Research raised shares of Trillium Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, April 6th.
A number of institutional investors have recently bought and sold shares of TRIL. Janus Capital Management LLC increased its position in Trillium Therapeutics by 0.3% in the fourth quarter. Janus Capital Management LLC now owns 571,203 shares of the biotechnology company’s stock worth $3,227,000 after buying an additional 1,619 shares in the last quarter. Baker BROS. Advisors LP purchased a new position in Trillium Therapeutics during the third quarter worth about $6,120,000. New Leaf Venture Partners L.L.C. purchased a new position in Trillium Therapeutics during the fourth quarter worth about $547,000. Polar Capital LLP purchased a new position in Trillium Therapeutics during the third quarter worth about $488,000. Finally, Susquehanna International Group LLP purchased a new position in Trillium Therapeutics during the third quarter worth about $372,000. 42.78% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at http://www.watchlistnews.com/brokerages-set-trillium-therapeutics-inc-tril-target-price-at-24-25/1206244.html.
Trillium Therapeutics (NASDAQ:TRIL) traded down 0.82% on Monday, reaching $6.05. 36,541 shares of the company were exchanged. Trillium Therapeutics has a 12-month low of $4.50 and a 12-month high of $17.70. The firm’s market capitalization is $47.46 million. The stock has a 50 day moving average of $6.21 and a 200 day moving average of $7.77.
About Trillium Therapeutics
Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.